Drug profile · INN
dactinomycin
DACTINOMYCIN
dactinomycin (DACTINOMYCIN) is a dna inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — dactinomycin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
dactinomycin (DACTINOMYCIN) is a dna inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dactinomycin?
dactinomycin (DACTINOMYCIN) is a dna inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dactinomycin?
DACTINOMYCIN is a marketed brand name for dactinomycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dactinomycin?
dactinomycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.